Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 +1.59%
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.
- Total revenue Mid-single digit percentage decline
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Hermès can regain momentum despite China weakness, Jefferies says
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
